Study of Antibody Responses to COVID-19 Vaccines
Author Information
Author(s): Bangaru Sandhya, Jackson Abigail M., Copps Jeffrey, Fernández-Quintero Monica L., Torres Jonathan L., Richey Sara T., Nogal Bartek, Sewall Leigh M., de la Peña Alba Torrents, Rehman Asma, Guebre-Xabier Mimi, Girard Bethany, Das Rituparna, Corbett-Helaire Kizzmekia S., Seder Robert A., Graham Barney S., Edwards Darin K., Patel Nita, Smith Gale, Ward Andrew B.
Primary Institution: The Scripps Research Institute
Hypothesis
How do mRNA-1273 and NVX-CoV2373 vaccines induce antibody responses?
Conclusion
Both mRNA-1273 and NVX-CoV2373 vaccines elicit diverse antibody responses, particularly targeting the NTD supersite, which is susceptible to variant mutations.
Supporting Evidence
- Both vaccines induce diverse polyclonal antibody responses to the N-terminal domain and receptor-binding domain of the Spike protein.
- NTD supersite antibodies were the most susceptible to variant mutations compared to other specificities.
- High-resolution cryo-EMPEM studies revealed extensive pAb responses to and around the supersite.
Takeaway
The study looked at how two COVID-19 vaccines make antibodies in people and found that they both create strong responses, especially to a specific part of the virus that can change.
Methodology
Electron microscopy-based polyclonal epitope mapping (EMPEM) was used to analyze serum from immunized non-human primates and clinical trial donors.
Limitations
The study primarily focused on two vaccines and may not represent responses to other COVID-19 vaccines.
Participant Demographics
The study involved non-human primates and clinical trial donors, including both male and female participants.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website